GLP-1 manufacturers bear liability for not warning US patients about NAION

US labels for Ozempic and Wegovy carry no NAION warning while the EMA flagged the risk in 2025, forming the basis of product liability suits.

Overview Debates Related claims Topics Sources

Childhood trauma leads people to develop psychosis

Insurers should be barred from setting premiums using genetic tests

More young people need to get their brain scanned

Satralizumab is a humanized monoclonal antibody designed to bind to soluble and membrane-bound interleukin-6 receptors, inhibiting interleukin-6-mediated inflammatory signaling

Thyroid eye disease is an inflammatory autoimmune condition affecting an estimated 16 women and 3 men per 100,000 population, commonly occurring in people with hyperthyroidism

Satralizumab is the first and only at-home subcutaneous treatment cleared by the FDA for adults with thyroid eye disease

Prior to satralizumab's approval, the FDA approved two intravenous thyroid eye disease treatments targeting the insulin-like growth factor 1 receptor: teprotumumab in 2020 and veligrotug in June 2026

Satralizumab was initially approved by the FDA in 2020 for neuromyelitis optica spectrum disorder, a rare neuroinflammatory condition

Satralizumab can be self-administered subcutaneously by a patient or caregiver following initial training from a healthcare provider

Although satralizumab's SatraGO-1 trial failed to meet its primary efficacy endpoint at week 24, satralizumab received approval based on efficacy results from satralizumab's SatraGO-2

On October 15, 2026, the U.S. Food and Drug Administration approved satralizumab-mwge (Enspryng), developed by Genentech, for adults with thyroid eye disease

The FDA approval of satralizumab for thyroid eye disease was based on data from the global phase 3 SatraGO program, which enrolled 258 patients across 19 countries

In satralizumab's phase 3 SatraGO-2 trial of active thyroid eye disease, 52.9% of satralizumab patients achieved a proptosis response of at least 2 mm reduction (vs. 23.4% placebo) and 60.7% achieved diplopia reduction (vs. 25.8% placebo)

Roche is studying satralizumab in additional neurologic, autoimmune, and inflammatory conditions that may benefit from interleukin-6 signaling inhibition

Thyroid eye disease symptoms can include eye swelling, eyelid retraction, a constant stare, proptosis, diplopia, and pain, which can be disfiguring, debilitating, or blinding

Roche reported that no new safety signals were identified for satralizumab across the phase 3 SatraGO-1 and SatraGO-2 clinical trials

Satralizumab's phase 3 SatraGO trial program demonstrated consistent efficacy in an overall trial population that included patients with both active and chronic thyroid eye disease

Genentech's interleukin-6 inhibitor tocilizumab has been studied off-label as a second-line therapy for patients with moderate-to-severe, glucocorticoid-resistant thyroid eye disease

Satralizumab dosing requires three initial loading injections at weeks 0, 2, and 4, followed by maintenance injections every 4 weeks

The most common adverse events reported for satralizumab in the SatraGO-1 and SatraGO-2 clinical trials were upper respiratory tract infections and elevated alanine aminotransferase levels